Achieve Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Accounting Policies (Policies)
Notes Tables
Notes Details

Collaboration Agreement - Additional Information (Detail)

v3.7.0.1

Collaboration Agreement - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended	4 Months Ended	18 Months Ended
	Apr. 24, 2015	Jan. 31, 2017	Aug. 31, 2016	Mar. 31, 2016	Apr. 24, 2015	Jun. 30, 2016	May 14, 2015
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue recognized				$ 2,940
Reversion rights period		90 days
Ionis Pharmaceuticals Inc. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Litigation settlement, upfront payment			$ 1,400
Royalty payment percentage			5.00%
Sale, license or other transaction payment percentage			50.00%
Ionis Pharmaceuticals Inc. [Member] \| Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Litigation settlement, success based payment			$ 5,000
Collaborative Arrangement [Member] \| Teva Pharmaceutical Industries Ltd. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from advance reimbursement research and development					$ 27,000
Hold-back amount and third-party expenses deducted from advanced reimbursement payment	$ 3,800				3,800
Hold-back amount deducted from advanced reimbursement payment	3,000				3,000
Third-party expenses deducted from advanced reimbursement payment					$ 800
Collaboration revenue recognized						$ 23,200
Collaborative Arrangement [Member] \| Ionis Pharmaceuticals Inc. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from advance reimbursement research and development, net amount	$ 23,200
Hold-back amount, requested payment percentage							30.00%

- Definition

Hold-back amount and third-party expenses deducted from collaboration agreement advanced reimbursement payment.

+ References

No definition available.

+ Details

Name:	ogxi_HoldBackAmountAndThirdPartyExpensesDeductedFromAdvancedReimbursementPayment
Namespace Prefix:	ogxi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Hold-back amount deduced from collaboration agreement advanced reimbursement payment.

+ References

No definition available.

+ Details

Name:	ogxi_HoldBackAmountDeducedFromAdvancedReimbursementPayment
Namespace Prefix:	ogxi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Hold-back amount, requested payment percentage.

+ References

No definition available.

+ Details

Name:	ogxi_HoldBackAmountRequestedPaymentPercentage
Namespace Prefix:	ogxi_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Litigation settlement, additional royalty payment as percentage of net sales of licensed product.

+ References

No definition available.

+ Details

Name:	ogxi_LitigationSettlementAdditionalRoyaltyPaymentAsPercentageOfNetSalesOfLicensedProduct
Namespace Prefix:	ogxi_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Litigation settlement, payment as percentage of money received from sale, license or other transaction of licensed product.

+ References

No definition available.

+ Details

Name:	ogxi_LitigationSettlementPaymentAsPercentageOfMoneyReceivedFromSaleLicenseOrOtherTransactionOfLicensedProduct
Namespace Prefix:	ogxi_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Proceeds from advance reimbursement research and development.

+ References

No definition available.

+ Details

Name:	ogxi_ProceedsFromAdvanceReimbursementResearchAndDevelopment
Namespace Prefix:	ogxi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Reversion rights period.

+ References

No definition available.

+ Details

Name:	ogxi_ReversionRightsPeriod
Namespace Prefix:	ogxi_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Third party expenses deducted from collaboration agreement advanced reimbursement payment.

+ References

No definition available.

+ Details

Name:	ogxi_ThirdPartyExpensesDeductedFromAdvancedReimbursementPayment
Namespace Prefix:	ogxi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of damages paid to the plaintiff in the legal matter.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

+ Details

Name:	us-gaap_LossContingencyDamagesPaidValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The difference between the maximum amount of estimated loss and the amount recorded as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6395354&loc=d3e12631-108344

+ Details

Name:	us-gaap_LossContingencyRangeOfPossibleLossPortionNotAccrued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Repayment received or receivable for expenses incurred on behalf of a client or customer, other than those reimbursements received by landlords from tenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 45
-Section 45
-Paragraph 23
-URI http://asc.fasb.org/extlink&oid=68075638&loc=d3e60722-111653

+ Details

Name:	us-gaap_ReimbursementRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=ogxi_IonisPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=ogxi_TevaPharmaceuticalIndustriesLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: